Marcus Schmidt

发表

Tivoli , Tuborg und Rheologie / Tivoli , Tuborg and Rhelogy

Marcus Schmidt, 1994 .

14 Working Techniques

Marcus Schmidt, Robert Glaum, Peer Schmidt, 2012 .

Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer

Dirk Hasenclever, Jan G Hengstler, Susanne Gebhard, 2008, Clinical Cancer Research.

Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer

Lajos Pusztai, Achim Rody, Marcus Schmidt, 2014, Genomics data.

Coordinates in the universe of node-negative breast cancer revisited.

Jan G Hengstler, Marcus Schmidt, Marcus Schmidt, 2009, Cancer research.

Gelsolin Is Associated with Longer Metastasis-free Survival and Reduced Cell Migration in Estrogen Receptor-positive Breast Cancer.

Jan G Hengstler, Jörg Rahnenführer, Karolina Edlund, 2015, Anticancer research.

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

Carsten Denkert, Stephan Wienert, Frederick Klauschen, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surface-enhanced Laser Desorption/Ionisation Time-of-flight Mass Spectrometry to Detect Breast Cancer Markers in Tears and Serum.

Marcus Schmidt, Marcus Schmidt, F. Grus, 2009, Cancer genomics & proteomics.

Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer

Jan G. Hengstler, Wiebke Schormann, Katja Ickstadt, 2011, Breast Cancer Research and Treatment.

A clinically relevant gene signature in triple negative and basal-like breast cancer

Lajos Pusztai, Achim Rody, Marcus Schmidt, 2010, Breast Cancer Research.

Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules

Alex Arenas, Carlos Caldas, Sergio Gomez, 2010, BMC Cancer.

Identification of sample annotation errors in gene expression datasets

Jan G. Hengstler, Jörg Rahnenführer, Johan Botling, 2015, Archives of Toxicology.

Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures

Lajos Pusztai, Eugen Ruckhäberle, Achim Rody, 2011, PloS one.

ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction

Holger Sültmann, Jan G. Hengstler, Jörg Rahnenführer, 2010, Clinical Cancer Research.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Xin Huang, Johannes Ettl, Marcus Schmidt, 2015, The Lancet. Oncology.

Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.

Kevin R Coombes, Lajos Pusztai, Eugen Ruckhäberle, 2012, European journal of cancer.